BY MARKETWIRE
-
Smith & Nephew shares jump as full-year outlook is upheld
The British clinical items manufacturer has actually preserved its expectation, as it just sees a minimal effect from United States tolls.
-
Hims & Hers stock soars on Wegovy deal with Novo
The partnership between Novo Nordisk and Hims & Hers is a response to Novo’s US rival Eli Lilly, which is behind the drug Zepbound and is collaborating with company Ro on tele…
-
Pfizer beats earnings expectations
Pfizer’s profits amounted to USD 13.7 bn, contrasted to assumptions of USD 14.0 bn.
-
AstraZeneca CEO warns against US tariffs on medicines
The Swedish-British drugmaker has actually simply launched its first-quarter outcomes, where chief executive officer alerts versus tolls, although that the firm has component of it…
-
Novartis reports continued sales growth of Genmab-developed sclerosis drug
Genmab will receive 10% in royalties from sales of Kesimpta.
-
German Merck buys US Springworks Therapeutics for nearly USD 4bn
Merck’s acquisition establishes the United States biotech business market evaluation at simply under USD 4bn.
-
MSD’s Q1 figures show growth and reveal tariff impact
MSD recognized sales of USD 15.53 bn in the very first quarter of this year, contrasted to experts’ assumptions of USD 15.33 bn.
-
Sanofi’s earnings soar on growing demand for blockbuster drug
Expectations for the full year are maintained despite tariff uncertainty.
-
Good news for Novo in the US: Compounding pharmacies to stop sales of Wegovy and Ozempic copies
With the court’s denial of the drug stores’ demand to remain to offer common variations of the medications, the target date to quit sales in May perseveres.
-
Analyst predicts trouble ahead for GN: Trade war could derail transformation
According to Nordea, the profession battle in between the United States and China can place a spanner in the jobs of GN’s passions to incorporate the team’s departments…
